On November 17, the Beijing Stock Exchange-listed company Xinghao Pharmaceutical announced that its wholly-owned subsidiary Guangdong Dingxin and the company's actual controller and general manager Yu Jizhong have been prosecuted by the People's Procuratorate of Yuhuatai District, Nanjing, on suspicion of bid-rigging. The product involved is octreotide injection from the seventh batch of the national centralized drug procurement program.
Actual Controller Identified as Principal Offender, Governance and Reputation Both Damaged
The procuratorate's indictment explicitly determined that Yu Jizhong, as the directly responsible person in charge of the unit crime, played a principal role in the joint crime and is therefore classified as the principal offender. Although Yu Jizhong is currently released on bail pending trial and continues to perform his duties normally, criminal prosecution directly impacts the stability of corporate governance. The involvement of the actual controller and core manager in a criminal case may not only affect the efficiency of daily operational decision-making, but if a guilty verdict is subsequently handed down, it will also trigger restrictions on the qualifications of the actual controller of a listed company, potentially causing management turmoil. Compared with the bromhexine injection case, which was also a case of bid collusion in centralized procurement but only received administrative penalties, the octreotide case has directly entered the criminal prosecution stage, indicating a more severe regulatory characterization. This case will not only expose the company to economic penalties such as fines and recovery of illegal gains, but may also result in being placed on the centralized procurement violation list and having subsequent bidding qualifications suspended, directly losing access to centralized procurement as a core market channel. In the longer term, the criminal record will severely damage the company's business reputation and negatively impact its CMC/CMO business expansion and industry cooperation.
Core Product Performance Under Pressure, Profit Foundation Hit by Compliance Incident
Octreotide injection was once the core growth engine for Xinghao Pharmaceutical. The product had a gross margin of 90.45% in 2022. After winning the bid in the seventh batch of national centralized procurement, it drove the company's anti-tumor and immunomodulator segment revenue to surge by 322.27%, making it the core driver of performance growth in 2023. However, after the bid-rigging incident was exposed, the product's winning bid price dropped from 17.28 yuan per vial to 8.99 yuan per vial, a decrease of 47.97%, directly causing the related segment revenue to decline by 37.66% year-on-year in 2024, with overall company revenue shrinking by 10.24% in tandem. Although the company has currently won a bid in the follow-up procurement, the room for price adjustment is limited, and the announcement disclosed that illegal gains from the product amounted to 21.8453 million yuan, which will likely be subject to recovery, further squeezing profit margins. The deeper problem lies in the fact that this case has exposed serious deficiencies in the company's compliance system, with institutional loopholes in the centralized procurement bidding process. Multiple products under Xinghao Pharmaceutical have participated in centralized procurement at various levels. If compliance risks spread to other products, the company's overall profit foundation will face a systemic shock.
Comments